Get the Stockscreener App
2.12
1.40%
-0.03
Oramed Pharmaceuticals Inc stock is traded at $2.12, with a volume of 61,152.
It is down -1.40% in the last 24 hours and up +0.95% over the past month.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.
See More
Previous Close:
$2.15
Open:
$2.17
24h Volume:
61,152
Relative Volume:
0.89
Market Cap:
$86.59M
Revenue:
$2.70M
Net Income/Loss:
$5.53M
P/E Ratio:
19.27
EPS:
0.11
Net Cash Flow:
$-10.55M
1W Performance:
-1.85%
1M Performance:
+0.95%
6M Performance:
-5.36%
1Y Performance:
-10.55%
1-Day Range:
$2.08
$2.18
1-Week Range:
$2.08
$2.26
52-Week Range:
$1.82
$3.09
Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile
Name
Oramed Pharmaceuticals Inc
Sector
Industry
Phone
646-844-1164
Address
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
Compare ORMP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORMP
Oramed Pharmaceuticals Inc
|
2.12 | 87.82M | 2.70M | 5.53M | -10.55M | 0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-12-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Feb-18-22 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-20-21 | Initiated | Canaccord Genuity | Buy |
| Feb-09-21 | Initiated | National Securities | Buy |
| Dec-03-20 | Initiated | Alliance Global Partners | Buy |
| Mar-11-20 | Initiated | Aegis Capital | Buy |
| Sep-11-19 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-17 | Resumed | B. Riley FBR, Inc. | Buy |
| May-26-16 | Reiterated | FBR Capital | Outperform |
| Dec-01-15 | Reiterated | H.C. Wainwright | Buy |
| Nov-19-15 | Initiated | FBR Capital | Outperform |
| Apr-13-15 | Resumed | MLV & Co | Buy |
| Jan-30-14 | Reiterated | Aegis Capital | Buy |
| Jan-08-14 | Reiterated | Aegis Capital | Buy |
| Jan-08-14 | Initiated | MLV & Co | Buy |
| Dec-03-13 | Initiated | Aegis Capital | Buy |
View All
Oramed Pharmaceuticals Inc Stock (ORMP) Latest News
What are analysts’ price targets for Oramed Pharmaceuticals Inc. in the next 12 monthsAI Powered Ideas With High Returns - jammulinksnews.com
How high can Oramed Pharmaceuticals Inc. stock goAI Swing Strategy Signal Forecasting System - Newser
Is Oramed Pharmaceuticals Inc. stock overvalued or undervaluedAI Powered Ideas With High Returns - jammulinksnews.com
Diabetes Pipeline 2025: Therapies Under Investigation, - openPR.com
Key External Factors That Drive Oramed Pharmaceuticals Inc. Stock Price MovementsConsistent Return Setup with Exit Strategy - Newser
How high can Oramed Pharmaceuticals Inc. stock price go in 2025Trend Following Ideas with Volume Confirmation - Newser
What are the technical indicators suggesting about Oramed Pharmaceuticals Inc.Advanced Screener Entry Points For Consistent Profits - jammulinksnews.com
How does Oramed Pharmaceuticals Inc. generate profit in a changing economyAI Powered Review For 2025 - jammulinksnews.com
Published on: 2025-07-30 11:09:17 - metal.it
What makes Oramed Pharmaceuticals Inc. stock price move sharplyHigh Reward Picks with Tight Risk Control - Newser
Published on: 2025-07-29 17:32:00 - metal.it
Oramed Pharmaceuticals Inc. Stock Support and Resistance Levels You Should KnowMulti-Bagger Detection with Trend Tools - Newser
Published on: 2025-07-28 21:44:50 - metal.it
What Technical Tools Say About Oramed Pharmaceuticals Inc. RecoveryWeekly Watchlist of High Movers Released - metal.it
How volatile is Oramed Pharmaceuticals Inc. stock compared to the marketGet daily expert analysis for smarter investing - jammulinksnews.com
Should I hold or sell Oramed Pharmaceuticals Inc. stock in 2025Capitalize on emerging market opportunities - jammulinksnews.com
Is it the right time to buy Oramed Pharmaceuticals Inc. stockExceptional stock performance - jammulinksnews.com
How high can Oramed Pharmaceuticals Inc. stock price go in 2025 Smart Chart Forecasting with AI Algorithms - Newser
Can a trend reversal in Oramed Pharmaceuticals Inc. lead to recovery Weekly Chart-Based Forecast for Traders - Newser
What is the dividend policy of Oramed Pharmaceuticals Inc. stockConsistent triple-digit returns - jammulinksnews.com
How does Oramed Pharmaceuticals Inc. compare to its industry peersGet daily expert analysis on top stocks - jammulinksnews.com
When is Oramed Pharmaceuticals Inc. stock expected to show significant growthUnlock expert market analysis instantly - jammulinksnews.com
Intrinsic Value of Oramed Pharmaceuticals Inc. Stock: Is It Undervalued or OvervaluedFree Stock Market Practical Discussion Forums - Newser
Oramed Pharmaceuticals Inc. Earnings Report Breakdown: What Investors Should KnowFree High-Accuracy Stock Picks - Newser
What analysts say about Oramed Pharmaceuticals Inc. stock outlookFree Stock Market Real-Time Monitoring - jammulinksnews.com
What drives Oramed Pharmaceuticals Inc. stock priceBreakout portfolio performance - Autocar Professional
How Oramed Pharmaceuticals Inc. stock reacts to Fed policy changesFree Trading Psychology Coaching - jammulinksnews.com
What analysts say about Oramed Pharmaceuticals Inc. stockFree Popular Stock Recommendations - Autocar Professional
Oramed Pharmaceuticals Inc. Stock Analysis and ForecastSky-high return potential - Autocar Professional
Oramed Pharm and Scilex Finalize Option Agreement - TipRanks
Oramed Pharmaceuticals enters option agreement with Scilex for warrant repurchase - MarketScreener
Is Oramed Pharmaceuticals Inc. a good long term investmentAccelerated capital growth - jammulinksnews.com
Oramed Pharmaceuticals Inc Stock (ORMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):